Pet Cancer Therapeutics Market Analysis

Pet Cancer Therapeutics Market Analysis

Based on species, the global market is segmented into dogs, cats and other species. The dogs segment dominated the market and was valued at USD 402 million in 2024.
 

• Dogs are more frequently diagnosed with cancers such as lymphoma, osteosarcoma, and mammary tumors. This leads to an increasing demand for therapeutic treatments for dogs solidifying its position in the market.
   
• For instance, according to a statistic published by the Veterinary Cancer Society, around 47% of dogs suffer from cancer, especially those dogs above age ten. This statistic elevated awareness towards the increasing demand and prevalence of cancer treatments for dogs over ten years as well as increasing age expectational gap. The need for pet cancer therapeutics is expected to grow steadily in aging dogs.
   
• In addition, the emergence of early diagnosis and effective treatment has driven the growth in the market.
   
• Furthermore, the growing awareness among pet owners along with a specific treatment for dogs has also aided towards helping this segment remain the biggest in this market.
   
• There has been much research done in the field including the drugs which have been approved for lymphoma which is a widely common form of cancer in dogs. These include the Tanovea (rabacfosadine injection) that was approved by the U.S FDA in 2021. There are many other clinical trials taking place such as the Calviri, Inc's 2022 vaccine against canine cancer study which further emphasizes the growth of this sector.

Based on the therapy, the global pet cancer therapeutics market is segmented into chemotherapy, immunotherapy, targeted therapy, and combination therapy. The chemotherapy segment accounted for the highest market share of 62.1% in 2024.
 

• Chemotherapy effectively targets and kill the cancer cells or inhibit their growth making it a preference as go-to treatment for most cancer including lymphoma and mast cell tumors.
   
• Since chemotherapy drugs are among the most potent in existence, achieving a recovery rate of more than 80% for conditions such as lymphoma is routine. This astonishing rate has been shown in dogs afflicted with cancer all over the world.
   
• Chemotherapy is one of the cornerstones of treatment in veterinary oncology and, with the increasing ownership of pets and subsequent awareness of animal health, the market opportunity continues to grow.
   

Based on the route of administration, the global pet cancer therapeutics market is segmented into oral and injection. The injection segment dominated the market in 2024 and is anticipated to reach USD 789 million by 2034.
 

• The use of injections arises from their ability to facilitate the administration of cancer treatment directly into the bloodstream or tumor.
   
• Injectable therapy including chemotherapy and immunotherapy agents expands to have increased absorption and targeting effect which has major advantages on many cancers seen in pets.
   
• These treatments are more favored for their precision and better control of side effects.
   
• As new injectable formulations are being developed, the need for injectable cancer therapeutics in veterinary practice is expected to remain strong, thus increasing the prominence of this segment in the market.
   

Based on cancer type, the global pet cancer therapeutics market is segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer, and other cancer types. The mast cell cancer segment is expected to grow at a 9.4% CAGR over the analysis period.
 

• The robust incidence of mast cell cancer can be explained by the high incidence of mast cell tumors in canines, especially within certain breeds such as Boxers, Bulldogs, and Retrievers.
   
• Pets are afflicted by a number of skin tumors, though mast cell tumors are the most common types of skin cancers found and often need prompt, effective treatment due to their aggressive nature.
   
• For instance, as reported by Morris Animal Foundation, about 16% to 21% of all skin tumors in pets consist elucidated mast cell tumors, which have different shapes and features. Their growth pattern differs also, with some growing slowly while others form diffuse lesions that are ulcerated and itchy.
   
• As a result, in combination with the proclivity of these tumors for malignancy and other complications, these factors have resulted in the mast cell cancers niche dominating the market.
   
• Their prevalence, along with the potential for malignancy and complications, has contributed to the dominance of the mast cell cancer segment in the market.

In 2024, the U.S. held a significant position in the North American pet cancer therapeutics market and projected to dominate throughout the forecast period with a CAGR of 9.3%.
 

• The U.S. leadership stemmed from the developed veterinary health system alongside high rates of pet ownership and growing consciousness regarding cancer therapy for pets.
   
• The country poses substantial resources in oncology surgery owing to the state-of-the-art technology, innovations, and diverse treatment modalities available such as chemotherapy, immunotherapy, and targeted therapy.
   
• In addition, the increasing instances of pet cancers in elderly pets is also a major factor contributing to the growth of these therapeutics.
   
• Furthermore, the existence of major veterinary pharmaceutical companies and animal health clinics services reinforced the position of the U.S. as a major factor in the development of the market in North America.
   

The pet cancer therapeutics market in Germany is estimated to grow at significant growth rate over the next few years.
 

• Germany’s market of cancer therapeutics for pets is expanding due to improved awareness of pet health, improvement in veterinary oncology, and growing pet ownership coupled with a greater need for specialized treatment.
   
• For example, Der Deutsche Heimtiermarkt 2021 reported that 47% of German households had pets, and there were altogether 34.7 million dogs, cats, small animals, and birds. The increase in pet ownership has created an awareness towards pet welfare, leading to increased spending on veterinary care and treatment of cancers.
   
• Since cancer is one of the prime causes of death for pet animals, this indicator points towards an increase in the demand for cancers diagnosis and treatments aids, which is further aids by the existing studies done in the country.
   

China held the prominent position in the Asia Pacific pet cancer therapeutics market during the analysis period.
 

• The growth of China can be linked with the increasing occurrence of pet cancer, growing concern among pet caregivers and vets addressing the issue, and improvement in veterinary techniques.
   
• Also, the strengthening of biotechnological companies in the country and the pet friendly policies of the government make the country more competitive for production in the veterinary drugs. Domestic companies innovation for affordable cancer treatment has further elevated the growth in the market.
   
• Furthermore, the growing awareness towards pet care and cancer treatment is enabling the need for advanced veterinary care in the country.
   
• Moreover, the market’s growth is further stemmed from the increasing demand for chemotherapy, immunotherapy and other oncological treatments for pets.
   

Brazil pet cancer therapeutics market is anticipated to witness high growth over the analysis timeframe in Latin America.
 

• Raising pet ownership trends and increasing awareness towards pet cancer treatment are encouraging advanced veterinary services in the country.
   
• Furthermore, increased acceptance towards innovative cancer interventions in pets, including chemotherapy, immunotherapy, and targeted therapies, is also fueling the market growth.
   
• Moreover, changes in the Brazilian veterinary healthcare system combined with more efficient cancer treatment medications are expected to improve the access to this treatment.
   
• Therefore, the aforementioned factors witnessed Brazil’s prominence in the Latin American market.
   

Saudi Arabia is anticipated to grow in the Middle East and African pet cancer therapeutics market.
 

• Saudi Arabia's urban population is increasingly owning pets due to wealth gain and is subsequently heightening the demand for advanced veterinary services.
   
• In addition, increasing awareness of pet health and cancer treatment, a growing number of pet owners are opting for specialized cancer treatments like chemotherapy and immunotherapy.
   
• Alongside, the growing investment in research and developments, the Brazilian veterinary healthcare infrastructure is also improving providing better access to advanced treatment.
   
• Thus, the aforementioned factors collectively turn Saudi Arabia into one of the leading markets for pet cancer therapeutics during the forecast period.